Profile data is unavailable for this security.
About the company
Par Drugs and Chemicals Limited is an India-based company engaged in manufacturing of active pharma ingredients (APIs) and fine chemicals for the domestic market as well as for exports to international markets. The Company manufactures a diverse range of antacid molecules. The Company’s products include magnesium hydroxide, magnesium trisilicate, magnesium carbonate, light magnesium oxide, magnesium oxide heavy, magnesium oxide USP, dried aluminum hydroxide gel, magaldrate, magnesium aluminum silicate hydrated, alma gate, hydrotalcite, aluminum hydroxide magnesium carbonate co-dried gel, aluminum-magnesium silicate BP, sodium aluminum silicate, precipitated silica, magnesium silicate, amorphous, colloidal silicon dioxide, and sucralfate USP. The Company owns and operates its manufacturing facilities at Bhavnagar in Gujarat. It has over four manufacturing blocks at Bhavnagar, which are for different products, having a capacity of approximately 9,700 metric tons per annum.
- Revenue in INR (TTM)1.06bn
- Net income in INR139.06m
- Incorporated1999
- Employees121.00
- LocationPar Drugs and Chemicals Ltd816, Nilamber Triumph,, Gotri Vasna RoadVADODARA 390007IndiaIND
- Phone+91 2 652991022
- Websitehttps://pardrugs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bal Pharma Ltd | 2.95bn | 68.32m | 1.20bn | 986.00 | 17.88 | 1.53 | 7.24 | 0.4054 | 4.20 | 4.20 | 187.56 | 49.20 | 0.8563 | 1.52 | 3.04 | 2,991,140.00 | 1.99 | 1.95 | 5.74 | 5.49 | 47.68 | 43.12 | 2.33 | 1.88 | 0.5781 | 1.04 | 0.6641 | 30.29 | -10.65 | 12.12 | -2.39 | -- | 29.98 | -- |
| Par Drugs and Chemicals Ltd | 1.06bn | 139.06m | 1.23bn | 121.00 | 8.83 | -- | 6.98 | 1.15 | 11.30 | 11.30 | 86.47 | -- | -- | -- | -- | 8,791,298.00 | -- | 13.79 | -- | 16.47 | 58.42 | 43.07 | 13.07 | 14.02 | -- | 137.75 | -- | -- | 5.58 | 12.57 | -7.88 | 22.90 | -4.68 | -- |
| Krebs Biochemicals And Industries Ltd | 230.23m | -228.62m | 1.26bn | 202.00 | -- | -- | -- | 5.49 | -10.60 | -10.60 | 10.68 | -74.60 | -- | -- | -- | 1,139,753.00 | -- | -16.90 | -- | -26.56 | 96.27 | 20.39 | -99.30 | -55.63 | 0.0359 | -2.42 | 3.65 | -- | -14.10 | 5.33 | -36.55 | -- | -17.65 | -- |
| Sotac Pharmaceuticals Ltd | 814.02m | 87.04m | 1.38bn | 67.00 | 15.88 | 2.48 | 9.12 | 1.70 | 7.87 | 7.87 | 73.61 | 50.39 | 0.6818 | 2.86 | 2.67 | 12,149,600.00 | 8.46 | 5.81 | 16.28 | 12.47 | 37.26 | 25.59 | 12.40 | 4.69 | 0.9737 | 2.30 | 0.3854 | -- | -6.59 | 27.66 | 124.25 | 146.89 | 11.66 | -- |
| Alpa Laboratories Limited | 1.14bn | 116.09m | 1.45bn | 453.00 | 12.53 | -- | 10.32 | 1.27 | 5.51 | 5.51 | 53.34 | -- | -- | -- | -- | 2,523,914.00 | -- | 8.59 | -- | 10.61 | 26.16 | 33.75 | 10.15 | 13.40 | -- | -17.25 | -- | -- | 3.41 | 5.52 | 16.25 | 60.11 | 34.92 | -- |
